NABI has another failure and is in a trading halt.
Fresh setback for Nabi's smoking-cessation vaccine. 17/10/12
Nabi Biopharmaceuticals NABI 0.00% said its Phase 2 study of its smoking-cessation vaccine didn't meet its primary endpoint, creating another setback for the drug.
http://www.marketwatch.com/story/fresh-setback-for-nabis-smoking-cessation-vaccine-2012-10-17